Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients

BackgroundStage III surgically resected melanoma is a disease at high risk of recurrence. Immune checkpoint inhibitors (ICIs) and the target therapy with BRAF and MEK inhibitors significantly changed the outcome of patients with metastatic melanoma and several studies have also shown their benefit i...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Francesca Romana Di Pietro, Sofia Verkhovskaia, Rosa Falcone, Giulia Poti, Maria Luigia Carbone, Maria Francesca Morelli, Albina Rita Zappalà, Roberto Morese, Zorika Christiana Di Rocco, Gabriele Piesco, Paolo Chesi, Cristina Maria Failla, Paolo Marchetti, Federica De Galitiis
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-08-01
Subjects:	melanoma adjuvant immunotherapy anti-PD-1 hyperprogression disease molecular profiling
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1437325/full

Similar Items

Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience
by: Francesca Romana Di Pietro, et al.
Published: (2024-10-01)

Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center
by: Rosa Falcone, et al.
Published: (2024-01-01)

Hyperprogression: A novel response pattern under immunotherapy
by: Xue‐jiao Han, et al.
Published: (2020-09-01)

Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
by: R. Riera-Sala, et al.
Published: (2023-09-01)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
by: Marta Brambilla, et al.
Published: (2020-12-01)

Advances of the Correlation between Driver Gene Status and Immunotherapy  in Non-small Cell Lung Cancer
by: Jie CHEN, et al.
Published: (2019-04-01)

Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature
by: Jan Skacel, et al.
Published: (2023-12-01)

Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians
by: Huijie Zhou, et al.
Published: (2023-03-01)

Case Report: Exploring delayed hyperprogressive disease: a case study of post-immunotherapy in lung cancer
by: Jie Zhou, et al.
Published: (2025-04-01)

Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report
by: Kosuke Masuda, et al.
Published: (2023-11-01)

A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice
by: Guo Hanfei, et al.
Published: (2021-12-01)

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
by: Sae Yumita, et al.
Published: (2023-03-01)

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Andrea Alberti, et al.
Published: (2022-06-01)

Comprehensive clinical and genetic characterization of hyperprogressive biliary tract cancer during PD-1 blockade monotherapy: case report and literature review
by: Kang-Xin Wang, et al.
Published: (2025-03-01)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
by: Zhanqi Wei, et al.
Published: (2022-05-01)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
by: Romain Varnier, et al.
Published: (2021-09-01)

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors
by: Yong Jun Choi, et al.
Published: (2020-10-01)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
by: H. S. Gabryś, et al.
Published: (2022-11-01)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
by: Xueping Wang, et al.
Published: (2020-05-01)

Dynamics of blood microsatellite instability (bMSI) burden predicts outcome of a patient treated with immune checkpoint inhibitors: a case report of hyperprogressive disease
by: Daria Kravchuk, et al.
Published: (2025-02-01)

Case report: Molecular characterization of adult atypical teratoid rhabdoid tumor and review of the literature
by: Miguel A. Hernandez-Rovira, et al.
Published: (2025-02-01)

Is there an association between lymph node size and hyperprogression in immunotherapy-treated patients?
by: Alkader Mohammad S., et al.
Published: (2024-03-01)

Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma
by: Chun-Hong Hu, et al.
Published: (2022-03-01)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
by: Zhi Ji, et al.
Published: (2019-07-01)

Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
by: Yaping Long, et al.
Published: (2023-09-01)

Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition
by: Yikun Li, et al.
Published: (2024-12-01)

Neutrophil-to-lymphocyte ratio as a predictive biomarker for hyperprogressive disease mediated by immune checkpoint inhibitors: a systematic review and meta-analysis
by: Bo Pei, et al.
Published: (2024-09-01)

First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review
by: Ya-Zhou Wang, et al.
Published: (2024-10-01)

Exploring the Frequency and Risk Factors of Hyperprogressive Disease in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
by: Caner Acar, et al.
Published: (2024-10-01)

Advanced Merkel cell carcinoma in setting of pembrolizumab therapy for squamous cell carcinoma
by: Henry Jeon, BSc, et al.
Published: (2024-05-01)

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
by: Daniela R. Montagna, et al.
Published: (2022-08-01)

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
by: Stefania Angelicola, et al.
Published: (2025-01-01)

MDM2 inhibitors in cancer immunotherapy: Current status and perspective
by: Qinru Zeng, et al.
Published: (2024-11-01)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
by: Shiyun Chen, et al.
Published: (2023-08-01)

Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis
by: Yan Chen, et al.
Published: (2020-07-01)

Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
by: Zijun Zhao, et al.
Published: (2022-08-01)

Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
by: Yangchun Gu, et al.
Published: (2021-01-01)

From discovery to licensure, the Adjuvant System story
by: Nathalie Garçon, et al.
Published: (2017-01-01)

Risk factors and nomogram predictive models for postsurgical progression/hyperprogression recurrence in hepatocellular carcinoma with macroscopic vascular invasion
by: Yiyue Huang, et al.
Published: (2024-11-01)

Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
by: Wang X, et al.
Published: (2023-01-01)